Public Companies
Psychedelic Stock Market Update | September, 2022
Although the Psychedelic Invest index had been performing well since the lows in May, September turned out to be a bad month for the market with the index…
Although the Psychedelic Invest index had been performing well since the lows in May, September turned out to be a bad month for the market with the index down -9.02%.
As you can see in the chart below, that’s because the large cap psychedelic stocks had a mixed performance in September.
While some stocks such as Relmada Therapeutics (RLMD) and Allied Corp (ALID) had positive performance, others such as Cybin (CYBN) Reunion Neuroscience (REUN) and MindMed (MNMD) brought down the index.
Although Relmada had positive performance in September – up 23.44% – as investors were looking forward to their Phase III results, the company ended up not meeting its primary endpoint, causing the stock to drop more than 80%.
What’s Up With MindMed?
In case you have missed it, our very own Adam Tubero was all over this story to explain what is going on at the company and why it was down more than 70% in September.
Cleaning Up the Index
Due to the macro environment and the performance of psychedelic-focused stocks over the past year, many companies in the space have begun to shut down or pivot away from psychedelics.
In September, Psychedelic Invest began investigating the amount of shutdowns in the space and concluded that as many as 15 psychedelic companies that were previously in our index have shut down in the past year. These include:
- Aion
- Captiva Verde
- Cypher Metaverse
- Empower Clinics
- Goodness Growth holdings
- Graph blockchain inc
- HAVN
- High Fusion
- Yourway (formerly Hollister Cannabis)
- Lattice Biologics
- M2Bio (formerly Wuhan)
- Minerco
- New Wave Holdings
- Roadman Corp
- Thoughtful brands
As unfortunate as this is to see, we don’t see this trend slowing down any time soon. There are many other psychedelic-focused companies trading right now that unless something miraculous occurs soon, will be forced to shutter.
Slowly, the psychedelic stock market is becoming more and more homogenous, with only the largest companies surviving.
Although Psychedelic Invest accurately called the bottom in May, 2022 for the overall sector, unfortunately it wasn’t the bottom for individual stocks.
-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics6 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation5 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics1 week ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics1 week ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Ketamine6 days ago
DEA poised to move cannabis to Schedule III
-
Psychedelics6 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Psychedelics6 days ago
Behold! A New Mushroom Emoji Has Arrived!